RBC
PACB icon

Romano Brothers & Co’s Pacific Biosciences PACB Stock Holding History

Romano Brothers & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-227
Closed -$1.86K – 760
2022
Q4 		$1.86K Buy
+227
New +$1.96K ﹤0.01% 944

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Romano Brothers & Co's PACB Position: Q1 2023 in Review

Romano Brothers & Co sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 227 shares — an estimated $1.86K sold.

Romano Brothers & Co first reported a position in PACB in Q4 2022 and held it in 1 quarter. The position peaked at $1.86K in Q4 2022. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

  • Romano Brothers & Co reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 227 Pacific Biosciences shares in Q1 2023, an estimated $1.86K.
  • Romano Brothers & Co first reported a position in Pacific Biosciences in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Pacific Biosciences position peaked at $1.86K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.